WO2003087341A3 - Targeted chromosomal mutagenesis using zinc finger nucleases - Google Patents

Targeted chromosomal mutagenesis using zinc finger nucleases Download PDF

Info

Publication number
WO2003087341A3
WO2003087341A3 PCT/US2003/002012 US0302012W WO03087341A3 WO 2003087341 A3 WO2003087341 A3 WO 2003087341A3 US 0302012 W US0302012 W US 0302012W WO 03087341 A3 WO03087341 A3 WO 03087341A3
Authority
WO
WIPO (PCT)
Prior art keywords
genetic material
present
provides
targeted
mutagenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/002012
Other languages
French (fr)
Other versions
WO2003087341A2 (en
Inventor
Dana Carroll
Marina Bibikova
Gary N Drews
Kent Gregory Golic
Mary M Golic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003584285A priority Critical patent/JP4968498B2/en
Priority to BRPI0307383A priority patent/BRPI0307383B1/en
Priority to AU2003251286A priority patent/AU2003251286B2/en
Priority to CA 2474486 priority patent/CA2474486C/en
Priority to EP03746527A priority patent/EP1476547B1/en
Priority to US10/502,565 priority patent/US8106255B2/en
Priority to DE2003610202 priority patent/DE60310202T2/en
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Priority to BR0307383A priority patent/BR0307383A/en
Publication of WO2003087341A2 publication Critical patent/WO2003087341A2/en
Publication of WO2003087341A3 publication Critical patent/WO2003087341A3/en
Anticipated expiration legal-status Critical
Priority to US13/314,490 priority patent/US9145565B2/en
Priority to US14/867,816 priority patent/US20160076045A1/en
Priority to US16/778,193 priority patent/US20200231979A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65—Genetically modified arthropods
    • A01K67/68—Genetically modified insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Catalysts (AREA)
  • Electrolytic Production Of Metals (AREA)

Abstract

The present invention provides for a method or methods of targeted genetic recombination or mutagenesis in a host cell or organism, and compositions useful for carrying out the method. The targeting method of the present invention exploits endogenous cellular mechanisms for homologous recombination and repair of double stranded breaks in genetic material. The present provides numerous improvements over previous mutagenesis methods, such advantages including that the method is generally applicable to a wide variety of organisms, the method is targeted so that the disadvantages associated with random insertion of DNA in to host genetic material are eliminated, and certain embodiments require relatively little manipulation of the host genetic material for success. Additionally, it provides a method that produces organisms with specific gene modifications in a short period of time.
PCT/US2003/002012 2002-01-23 2003-01-22 Targeted chromosomal mutagenesis using zinc finger nucleases Ceased WO2003087341A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US10/502,565 US8106255B2 (en) 2002-01-23 2003-01-22 Targeted chromosomal mutagenasis using zinc finger nucleases
BRPI0307383A BRPI0307383B1 (en) 2002-01-23 2003-01-22 directed genetic recombination method in host plant cell
AU2003251286A AU2003251286B2 (en) 2002-01-23 2003-01-22 Targeted chromosomal mutagenesis using zinc finger nucleases
CA 2474486 CA2474486C (en) 2002-01-23 2003-01-22 Targeted chromosomal mutagenesis using zinc finger nucleases
EP03746527A EP1476547B1 (en) 2002-01-23 2003-01-22 Targeted chromosomal mutagenesis using zinc finger nucleases
DE2003610202 DE60310202T2 (en) 2002-01-23 2003-01-22 TARGETED CHROMOSOMAL MUTAGENESIS WITH ZINC FINGERUCLEASES
BR0307383A BR0307383A (en) 2002-01-23 2003-01-22 Target chromosomal mutagenesis using zinc branch nucleases
JP2003584285A JP4968498B2 (en) 2002-01-23 2003-01-22 Targeted chromosomal mutagenesis using zinc finger nuclease
US13/314,490 US9145565B2 (en) 2002-01-23 2011-12-08 Targeted chromosomal mutagenesis using zinc finger nucleases
US14/867,816 US20160076045A1 (en) 2002-01-23 2015-09-28 Targeted chromosomal mutagenesis using zinc finger nucleases
US16/778,193 US20200231979A1 (en) 2002-01-23 2020-01-31 Targeted chromosomal mutagenesis using zinc finger nucleases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35103502P 2002-01-23 2002-01-23
US60/351,035 2002-01-23

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10502565 A-371-Of-International 2003-01-22
US10/502,565 A-371-Of-International US8106255B2 (en) 2002-01-23 2003-01-22 Targeted chromosomal mutagenasis using zinc finger nucleases
US13/314,490 Continuation US9145565B2 (en) 2002-01-23 2011-12-08 Targeted chromosomal mutagenesis using zinc finger nucleases

Publications (2)

Publication Number Publication Date
WO2003087341A2 WO2003087341A2 (en) 2003-10-23
WO2003087341A3 true WO2003087341A3 (en) 2004-04-29

Family

ID=29250450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002012 Ceased WO2003087341A2 (en) 2002-01-23 2003-01-22 Targeted chromosomal mutagenesis using zinc finger nucleases

Country Status (10)

Country Link
US (4) US8106255B2 (en)
EP (1) EP1476547B1 (en)
JP (2) JP4968498B2 (en)
CN (1) CN100575485C (en)
AT (1) ATE347593T1 (en)
AU (1) AU2003251286B2 (en)
BR (2) BR0307383A (en)
CA (1) CA2474486C (en)
DE (1) DE60310202T2 (en)
WO (1) WO2003087341A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591592B2 (en) 2020-04-24 2023-02-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells using microcarriers

Families Citing this family (448)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
JP4555292B2 (en) * 2003-08-08 2010-09-29 サンガモ バイオサイエンシズ インコーポレイテッド Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
WO2005028630A2 (en) 2003-09-19 2005-03-31 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005100393A1 (en) 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
KR20070060115A (en) * 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 Compositions and Methods for Protein Production
AU2006272634B2 (en) 2005-07-26 2013-01-24 Sangamo Therapeutics, Inc. Targeted integration and expression of exogenous nucleic acid sequences
AU2012245168B2 (en) * 2005-07-26 2014-12-11 Sangamo Therapeutics, Inc. Targeted Integration and Expression of Exogenous Nucleic Acid Sequences
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
WO2007081647A2 (en) * 2006-01-03 2007-07-19 The Scripps Research Institute Zinc finger domains specifically binding agc
US20070266449A1 (en) * 2006-05-12 2007-11-15 Zivin Robert A Generation of animal models
AU2007254251A1 (en) * 2006-05-19 2007-11-29 Sangamo Therapeutics, Inc. Methods and compositions for inactivation of dihydrofolate reductase
ES2465996T3 (en) 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Methods and compositions for genetic inactivation
JP5266210B2 (en) * 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド Modified cleavage half-domain
SI2049663T1 (en) * 2006-08-11 2015-12-31 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
US9217026B2 (en) * 2006-11-13 2015-12-22 Sangamo Biosciences, Inc. Method of inactivating a glucocorticoid receptor gene in an isolated cell
KR101520507B1 (en) * 2006-12-14 2015-05-29 다우 아그로사이언시즈 엘엘씨 Optimized non-regular zinc finger protein
US8748146B2 (en) * 2007-04-19 2014-06-10 Celexion, Llc Engineered nucleases and their uses for nucleic acid assembly
WO2008133938A2 (en) 2007-04-26 2008-11-06 Sangamo Biosciences, Inc. Targeted integration into the ppp1r12c locus
JP5666903B2 (en) 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for enhancing transgene expression
CN101849010A (en) 2007-06-29 2010-09-29 先锋高级育种国际公司 Methods for altering the genome of a monocot plant cell
AU2008275649B2 (en) 2007-07-12 2013-09-05 Sangamo Therapeutics, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
DK2205749T3 (en) * 2007-09-27 2016-08-22 Dow Agrosciences Llc MODIFIED PROTEINS zinc finger, which target the 5-enolpyruvylshikimate-3-phosphate synthase genes
US20090203140A1 (en) * 2007-09-27 2009-08-13 Sangamo Biosciences, Inc. Genomic editing in zebrafish using zinc finger nucleases
CA2700231C (en) * 2007-09-27 2018-09-18 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US20110014616A1 (en) * 2009-06-30 2011-01-20 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
AU2008317354B2 (en) * 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
EP2215252A4 (en) * 2007-12-07 2011-01-26 Prec Biosciences Inc MEGANUCLEASES DESIGNED RATIONALLY WITH IDENTIFICATION SEQUENCES FOUND IN HUMAN GENOME DNAASE HYPERSENSIVE REGIONS
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
EP2281050B1 (en) 2008-04-14 2014-04-02 Sangamo BioSciences, Inc. Linear donor constructs for targeted integration
WO2009146179A1 (en) * 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
EP2279250A4 (en) * 2008-04-28 2011-10-12 Prec Biosciences Inc FUSION MOLECULES OF DNA BINDING PROTEINS AND EFFECTOR DOMAINS DESIGNED RATIONALALLY
DK3211075T3 (en) 2008-07-14 2019-01-21 Prec Biosciences Inc RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF
SG191561A1 (en) 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration
EP2180058A1 (en) * 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
WO2010053518A2 (en) * 2008-10-29 2010-05-14 Sangamo Biosciences, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
EP3156494B8 (en) * 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110016542A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Canine genome editing with zinc finger nucleases
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023159A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Ovine genome editing with zinc finger nucleases
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023157A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Equine genome editing with zinc finger nucleases
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
KR101683928B1 (en) 2008-12-17 2016-12-07 다우 아그로사이언시즈 엘엘씨 Targeted integration into the Zp15 locus
US8871905B2 (en) * 2009-03-20 2014-10-28 Sangamo Biosciences, Inc. Modification of CXCR4 using engineered zinc finger proteins
AU2010235161B2 (en) * 2009-04-09 2015-01-22 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011005849A1 (en) 2009-07-08 2011-01-13 Cellular Dynamics International, Inc. Modified ips cells having a mutant form of human immunodeficiency virus (hiv) cellular entry gene
CN102858985A (en) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 Method for genome editing
WO2011011767A1 (en) * 2009-07-24 2011-01-27 Sigma-Aldrich Co. Method for genome editing
JP5866283B2 (en) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for treating trinucleotide repeat disease
KR102262704B1 (en) 2009-08-11 2021-06-09 상가모 테라퓨틱스, 인코포레이티드 Organisms homozygous for targeted modification
EP2493288B1 (en) * 2009-10-28 2015-02-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Homologous recombination in the oocyte
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011078662A1 (en) * 2009-12-21 2011-06-30 Keygene N.V. Dsrna for improved genetic modification of plant dna
NZ600546A (en) * 2010-01-22 2014-08-29 Dow Agrosciences Llc Excision of transgenes in genetically modified organisms
WO2011091324A2 (en) * 2010-01-22 2011-07-28 The Scripps Research Institute Methods of generating zinc finger nucleases having altered activity
KR101866578B1 (en) 2010-01-22 2018-06-11 다우 아그로사이언시즈 엘엘씨 Targeted genomic alteration
EP3594333B1 (en) 2010-02-08 2023-11-01 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
EP2534163B1 (en) 2010-02-09 2015-11-04 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US8771985B2 (en) 2010-04-26 2014-07-08 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using zinc-finger nucleases
JP6208580B2 (en) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド Novel DNA binding protein and use thereof
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
WO2012012738A1 (en) * 2010-07-23 2012-01-26 Sigma-Aldrich Co., Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
WO2012018726A1 (en) * 2010-08-02 2012-02-09 Cellectis Sa Method for increasing double-strand break-induced gene targeting
CA2811364C (en) 2010-09-27 2022-01-04 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
EP2627665B1 (en) 2010-10-12 2015-12-16 The Children's Hospital Of Philadelphia Methods and compositions for treating hemophilia B
WO2012088339A2 (en) 2010-12-22 2012-06-28 Genia Technologies, Inc. Nanopore-based single dna molecule characterization using speed bumps
WO2012094132A1 (en) 2011-01-05 2012-07-12 Sangamo Biosciences, Inc. Methods and compositions for gene correction
CN102174649B (en) * 2011-01-18 2013-06-12 陕西师范大学 Method for rapidly detecting zinc-finger nuclease mediated gene fixed point integration
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
CN102206631A (en) * 2011-03-08 2011-10-05 西北农林科技大学 Open-source method for screening zinc finger proteins targeted combined with target sites of human DYRK1A gene
CN102358902B (en) * 2011-04-02 2013-01-02 西南大学 Silkworm fibroin heavy-chain gene mutation sequence and mutation method and application
WO2012152912A1 (en) 2011-05-12 2012-11-15 Newvectys Genetically modified pig as a cancer prone model
AU2012267270B2 (en) 2011-06-08 2015-06-11 Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej Sequence-specific engineered ribonuclease H and the method for determining the sequence preference of DNA-RNA hybrid binding proteins
US9161995B2 (en) 2011-07-25 2015-10-20 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
AU2012312260B2 (en) 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
JP6188703B2 (en) 2011-10-27 2017-08-30 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for modifying the HPRT locus
AU2012340213B2 (en) 2011-11-16 2017-12-07 Sangamo Therapeutics, Inc. Modified DNA-binding proteins and uses thereof
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
CN108285491B (en) 2012-02-29 2021-08-10 桑格摩生物科学股份有限公司 Methods and compositions for treating huntington's disease
IN2014DN09261A (en) 2012-04-25 2015-07-10 Regeneron Pharma
CA2872124C (en) * 2012-05-02 2022-05-03 Dow Agrosciences Llc Plant with targeted modification of the endogenous malate dehydrogenase gene
AU2013259647B2 (en) 2012-05-07 2018-11-08 Corteva Agriscience Llc Methods and compositions for nuclease-mediated targeted integration of transgenes
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CA2876095A1 (en) 2012-06-15 2013-12-19 Genia Technologies, Inc. Chip set-up and high-accuracy nucleic acid sequencing
EP2861737B1 (en) * 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
DK3444342T3 (en) 2012-07-11 2020-08-24 Sangamo Therapeutics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL DEPOSIT DISEASES
US10648001B2 (en) * 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
US10058078B2 (en) 2012-07-31 2018-08-28 Recombinetics, Inc. Production of FMDV-resistant livestock by allele substitution
SI2890780T1 (en) 2012-08-29 2020-11-30 Sangamo Therapeutics, Inc. Methods and compositions for treating a genetic condition
CA2884162C (en) * 2012-09-07 2020-12-29 Dow Agrosciences Llc Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA118090C2 (en) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі METHOD OF THE METHER OF THE METHOD OF THE INTEGRED EMBLED SUBSTITUTION OF NUCLEIC NUCLE OF NUCLEIC ACID AND NON-NUCLIC ACID AND NON-SPECIAL SPECIES
UA119135C2 (en) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Engineered transgene integration platform (etip) for gene targeting and trait stacking
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
CN103215234B (en) * 2012-11-09 2014-12-10 陕西师范大学 Adenovirus with zinc finger nuclease expression element and donor DNA, and construction method and application
US9605309B2 (en) 2012-11-09 2017-03-28 Genia Technologies, Inc. Nucleic acid sequencing using tags
WO2014089212A1 (en) 2012-12-05 2014-06-12 Sangamo Biosciences, Inc. Methods and compositions for regulation of metabolic disorders
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CA2895117A1 (en) 2012-12-13 2014-06-19 James W. Bing Precision gene targeting to a particular locus in maize
WO2014097113A2 (en) 2012-12-18 2014-06-26 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
ES2953523T3 (en) 2012-12-27 2023-11-14 Keygene Nv Method for inducing a directed translocation in a plant
MX2015010841A (en) 2013-02-20 2016-05-09 Regeneron Pharma Genetic modification of rats.
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
RU2694686C2 (en) 2013-03-12 2019-07-16 Е.И.Дюпон Де Немур Энд Компани Methods for identifying variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
PT2971039T (en) 2013-03-14 2020-05-06 Immusoft Corp Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
MX374090B (en) 2013-03-14 2025-03-05 Caribou Biosciences Inc COMPOSITIONS AND METHODS OF NUCLEIC ACIDS DIRECTED TO NUCLEIC ACID.
JP6346266B2 (en) 2013-03-21 2018-06-20 サンガモ セラピューティクス， インコーポレイテッド Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2981166B1 (en) 2013-04-05 2020-09-09 Dow AgroSciences LLC Methods and compositions for integration of an exogenous sequence within the genome of plants
SI2986729T1 (en) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US10604771B2 (en) * 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN105683376A (en) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 Methods and compositions for treating genetic conditions
CN105531372A (en) * 2013-06-14 2016-04-27 塞尔克蒂斯股份有限公司 Non-transgenic genome editing methods in plants
US10563225B2 (en) * 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
WO2015017866A1 (en) 2013-08-02 2015-02-05 Enevolv, Inc. Processes and host cells for genome, pathway, and biomolecular engineering
AU2014312295C1 (en) 2013-08-28 2020-08-13 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
KR102238137B1 (en) 2013-09-04 2021-04-09 다우 아그로사이언시즈 엘엘씨 Rapid targeting analysis in crops for determining donor insertion
CN105899665B (en) 2013-10-17 2019-10-22 桑格摩生物科学股份有限公司 Delivery methods and compositions for nuclease-mediated genome engineering
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
CN105723222B (en) 2013-10-23 2019-01-22 吉尼亚科技公司 High-speed molecular sensing using nanopores
US9567630B2 (en) 2013-10-23 2017-02-14 Genia Technologies, Inc. Methods for forming lipid bilayers on biochips
UY35814A (en) 2013-11-04 2015-05-29 Dow Agrosciences Llc ? OPTIMAL PLACES FOR SOYBEAN ?.
MX358066B (en) 2013-11-04 2018-08-03 Dow Agrosciences Llc Optimal soybean loci.
KR102269769B1 (en) 2013-11-04 2021-06-28 코르테바 애그리사이언스 엘엘씨 Optimal maize loci
KR102269371B1 (en) 2013-11-04 2021-06-28 코르테바 애그리사이언스 엘엘씨 Optimal maize loci
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
HUE044540T2 (en) 2013-11-13 2019-10-28 Childrens Medical Center Nuclease-mediated regulation of gene expression
WO2015073867A1 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Engineering neural stem cells using homologous recombination
DK3080274T3 (en) 2013-12-09 2020-08-31 Sangamo Therapeutics Inc Methods and compositions for genome manipulation
SMT201800653T1 (en) 2013-12-11 2019-01-11 Regeneron Pharma Methods and compositions for the targeted modification of a genome
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
JP2017505756A (en) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション Soluble high molecular weight (HMW) tau species and uses thereof
US10774338B2 (en) 2014-01-16 2020-09-15 The Regents Of The University Of California Generation of heritable chimeric plant traits
WO2015117081A2 (en) 2014-02-03 2015-08-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a beta thalessemia
WO2015122967A1 (en) 2014-02-13 2015-08-20 Clontech Laboratories, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US10036034B2 (en) 2014-02-13 2018-07-31 Nutech Ventures Sequences involved in plant yield and methods of using
US10323251B2 (en) 2014-02-19 2019-06-18 National Research And Development Agency National Agriculture And Food Research Organization Method utilizing piggybac transposon and transposase to introduce mutation into target DNA in a plant cell
AU2015218576B2 (en) 2014-02-24 2020-02-27 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
WO2015129686A1 (en) 2014-02-25 2015-09-03 国立研究開発法人 農業生物資源研究所 Plant cell having mutation introduced into target dna, and method for producing same
SG11201609211VA (en) 2014-03-05 2016-12-29 Nat Univ Corp Univ Kobe Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
CN106459894B (en) 2014-03-18 2020-02-18 桑格摩生物科学股份有限公司 Methods and compositions for modulating zinc finger protein expression
WO2015164748A1 (en) 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
WO2015168125A1 (en) 2014-04-28 2015-11-05 Recombinetics, Inc. Multiplex gene editing in swine
RU2691102C2 (en) 2014-05-08 2019-06-11 Сангамо Байосайенсиз, Инк. Methods and compositions for treating huntington's disease
AU2015259191B2 (en) 2014-05-13 2019-03-21 Sangamo Therapeutics, Inc. Methods and compositions for prevention or treatment of a disease
EP3152319A4 (en) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Methods and compositions for nuclease design
RS60359B1 (en) 2014-06-06 2020-07-31 Regeneron Pharma Methods and compositions for modifying a targeted locus
CN106659290A (en) * 2014-06-19 2017-05-10 高露洁-棕榄公司 Oral Care Appliances
HUE049405T2 (en) 2014-06-23 2020-09-28 Regeneron Pharma Nuclease-mediated DNA assembly
KR102386101B1 (en) 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for targeted genetic modifications and methods of use
WO2016005449A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
HUE055583T2 (en) 2014-09-16 2021-12-28 Sangamo Therapeutics Inc Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
EP3197272A4 (en) 2014-09-23 2018-05-23 AgGenetics, Inc. Materials and methods for producing animals with short hair
DK3207124T3 (en) 2014-10-15 2019-08-12 Regeneron Pharma METHODS AND COMPOSITIONS FOR GENERATION OR STORAGE OF PLURIPOTENT CELLS
US10920215B2 (en) 2014-11-04 2021-02-16 National University Corporation Kobe University Method for modifying genome sequence to introduce specific mutation to targeted DNA sequence by base-removal reaction, and molecular complex used therein
JP2017533716A (en) 2014-11-12 2017-11-16 リコンビネティクス・インコーポレイテッドＲｅｃｏｍｂｉｎｅｔｉｃｓ，Ｉｎｃ． A heterozygous modification of the tumor suppressor gene and a porcine model of neurofibromatosis type 1
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
ES2731437T3 (en) 2014-11-21 2019-11-15 Regeneron Pharma Methods and compositions for directed genetic modification through the use of guide RNA pairs
RU2020122439A (en) 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. NON-HUMAN ANIMALS EXPRESSING HUMANIZED CD3 COMPLEX
CN104450785A (en) * 2014-12-08 2015-03-25 复旦大学 Genome editing method using attachment carrier for encoding targeted endonuclease and kit
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
KR102530821B1 (en) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for targeted genetic modification through single-step multiple targeting
EP3247366A4 (en) 2015-01-21 2018-10-31 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
AU2016243052C1 (en) 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
MX382223B (en) 2015-05-12 2025-03-13 Sangamo Therapeutics Inc NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSION.
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2017010423A1 (en) 2015-07-10 2017-01-19 中外製薬株式会社 Non-human animal having human cd3 gene substituted for endogenous cd3 gene
EP3322297B1 (en) 2015-07-13 2024-12-04 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
ES2938623T3 (en) 2015-09-09 2023-04-13 Univ Kobe Nat Univ Corp Method for converting a genome sequence of a gram-positive bacterium by specific nucleic acid base conversion of a targeted DNA sequence and the molecular complex used therein
WO2017053753A1 (en) 2015-09-23 2017-03-30 Sangamo Biosciences, Inc. Htt repressors and uses thereof
WO2017075261A1 (en) 2015-10-27 2017-05-04 Recombinetics, Inc. Engineering of humanized car t-cells and platelets by genetic complementation
CA3002524A1 (en) 2015-10-28 2017-05-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor viii expression cassettes and methods of use thereof
WO2017075538A1 (en) 2015-10-29 2017-05-04 Amyris, Inc. Compositions and methods for production of myrcene
WO2017079428A1 (en) 2015-11-04 2017-05-11 President And Fellows Of Harvard College Site specific germline modification
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
ES2914623T3 (en) 2015-11-27 2022-06-14 Univ Kobe Nat Univ Corp Method for converting a genomic sequence of a monocot plant in which a nucleic acid base in the target DNA sequence is specifically converted and the molecular complex used therein
AU2016369490C1 (en) 2015-12-18 2021-12-23 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
IL297018A (en) 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Targeted disruption of the mhc cell receptor
CA3010738A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
EP3411056A4 (en) 2016-02-02 2019-10-02 Sangamo Therapeutics, Inc. COMPOSITIONS FOR BINDING DNA BINDING DOMAINS AND CLEAVAGE DOMAINS
CN117925730A (en) 2016-04-21 2024-04-26 国立大学法人神户大学 Method for improving mutation introduction efficiency in genome sequence modification technology, and molecular complex used therein
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHODS FOR SELECTIVE MULTIPLICATION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
EP3484870B1 (en) 2016-07-13 2022-11-16 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
JP2019523009A (en) 2016-07-29 2019-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Mice having mutations leading to expression of C-terminal truncated fibrillin-1
WO2018029034A1 (en) 2016-08-09 2018-02-15 Vib Vzw Cellulose synthase inhibitors and mutant plants
WO2018035159A1 (en) 2016-08-15 2018-02-22 Enevolv, Inc. Molecule sensor systems
JP7125347B2 (en) * 2016-08-22 2022-08-24 中外製薬株式会社 Genetically Modified Non-Human Animals Expressing Human GPC3 Polypeptides
LT3504229T (en) 2016-08-24 2021-12-10 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
WO2018049009A2 (en) 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
WO2018057790A1 (en) 2016-09-21 2018-03-29 Recombinetics, Inc. Animal models for cardiomyopathy
ES2925644T3 (en) 2016-10-04 2022-10-19 Prec Biosciences Inc Costimulatory domains for use in genetically modified cells
GB201617559D0 (en) 2016-10-17 2016-11-30 University Court Of The University Of Edinburgh The Swine comprising modified cd163 and associated methods
CA3039673A1 (en) 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
JP7108608B2 (en) 2016-10-31 2022-07-28 サンガモ セラピューティクス， インコーポレイテッド Genetic modification of SCID-associated genes in hematopoietic stem and progenitor cells
WO2018093554A1 (en) * 2016-11-21 2018-05-24 Dow Agrosciences Llc Site specific integration of a transgne using intra-genomic recombination via a non-homologous end joining repair pathway
JP7416406B2 (en) 2016-12-08 2024-01-17 ケース ウェスタン リザーブ ユニバーシティ Methods and compositions for increasing functional myelin production
NZ755816A (en) 2017-01-19 2026-03-27 Omniab Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
IL314915B1 (en) 2017-01-23 2026-02-01 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
EP3604519A4 (en) 2017-03-22 2021-01-06 National University Corporation Kobe University METHOD OF NUCLEIC ACID SEQUENCE CONVERSION OF A CELL WITH SPECIFIC NUCLEIC ACID BASE CONVERSION OF TARGETED DNA USING ENDOGENIC DNA-MODIFYING ENZYME AND MOLECULAR COMPLEXES USED IN IT
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2020518245A (en) 2017-05-03 2020-06-25 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for modification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene
EP4029943A1 (en) 2017-05-08 2022-07-20 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
EP3409104A1 (en) 2017-05-31 2018-12-05 Vilmorin et Cie Tomato plant resistant to tomato yellow leaf curl virus, powdery mildew, and nematodes
EP3409106A1 (en) 2017-06-01 2018-12-05 Vilmorin et Cie Tolerance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus (tbrfv)
WO2020249996A1 (en) 2019-06-14 2020-12-17 Vilmorin & Cie Resistance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus
MX2019014661A (en) 2017-06-05 2020-07-29 Regeneron Pharma Empty
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
CA3068634A1 (en) 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
MX2019015505A (en) 2017-06-30 2020-07-28 Inscripta Inc Automated cell processing methods, modules, instruments, and systems.
CA3068465A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN110891419A (en) 2017-07-31 2020-03-17 瑞泽恩制药公司 Evaluation of CRISPR/CAS-induced in vivo recombination with exogenous donor nucleic acids
CN111182790A (en) 2017-07-31 2020-05-19 瑞泽恩制药公司 CRISPR reporter non-human animals and uses thereof
WO2019028032A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Cas-transgenic mouse embryonic stem cells and mice and uses thereof
CA3071683A1 (en) 2017-08-08 2019-02-14 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
WO2019033053A1 (en) 2017-08-11 2019-02-14 Recombinetics, Inc. INDUCIBLE DISEASE MODELS, METHODS OF MAKING AND USING THEM IN TISSUE COMPLEMENTATION
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
US11697822B2 (en) 2017-08-29 2023-07-11 KWS SAAT SE & Co. KGaA Blue aleurone and other segregation systems
CA3076249A1 (en) 2017-09-21 2019-03-28 The Brigham And Women's Hospital, Inc. Isolation, preservation, compositions and uses of extracts from justicia plants
MX394999B (en) 2017-09-29 2025-03-24 Regeneron Pharma Non-human animals comprising a humanized
EP3687621A4 (en) 2017-09-30 2021-08-11 Inscripta, Inc. CONTINUOUS FLOW ELECTROPORATION INSTRUMENTATION
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US20200299658A1 (en) 2017-11-01 2020-09-24 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
EP3706766A4 (en) 2017-11-09 2021-08-18 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible sh2-containing protein (cish) gene
WO2019099744A1 (en) 2017-11-15 2019-05-23 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3715454A4 (en) 2017-11-22 2021-08-18 National University Corporation Kobe University COMPLEX FOR SAFE GENE EDITION WITH LOW SIDE EFFECTS, AND NUCLEIC ACID CODING THIS
CA3088788A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
JP7483612B2 (en) 2018-01-17 2024-05-15 バーテックス ファーマシューティカルズ インコーポレイテッド Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
MA51619A (en) 2018-01-17 2021-04-14 Vertex Pharma DNA-DEPENDENT KINASE PROTEIN INHIBITORS
CA3089587A1 (en) 2018-02-08 2019-08-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases
CA3091143A1 (en) 2018-02-15 2019-08-22 Memorial Sloan-Kettering Cancer Center Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
CN111936617A (en) 2018-03-16 2020-11-13 益缪索夫特公司 B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders, and enhance muscle growth and strength
CN111885915B (en) 2018-03-19 2023-04-28 瑞泽恩制药公司 Transcriptional modulation in animals using the CRISPR/Cas system
JP6727680B2 (en) 2018-03-26 2020-07-22 国立大学法人神戸大学 Method for modifying target site of double-stranded DNA possessed by cell
WO2019190874A1 (en) 2018-03-29 2019-10-03 Inscripta, Inc. Automated control of cell growth rates for induction and transformation
KR20210020873A (en) 2018-04-05 2021-02-24 주노 쎄러퓨티크스 인코퍼레이티드 Τ cells expressing recombinant receptors, related polynucleotides and methods
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
US10376889B1 (en) 2018-04-13 2019-08-13 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
WO2019204457A1 (en) 2018-04-18 2019-10-24 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (htt)
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
AU2019292919A1 (en) 2018-06-30 2021-03-11 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
EP3831946A4 (en) 2018-07-31 2022-08-10 The University of Tokyo Membrane protein activity measurement method
CN112585266A (en) 2018-08-07 2021-03-30 摩大力斯医疗株式会社 Novel transcriptional activator
CN109097370A (en) * 2018-08-08 2018-12-28 华南农业大学 A method of regulation tea tree fine hair formation
EP3607819A1 (en) 2018-08-10 2020-02-12 Vilmorin et Cie Resistance to xanthomonas campestris pv. campestris (xcc) in cauliflower
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
JP7541508B2 (en) 2018-08-23 2024-08-28 サンガモ セラピューティクス， インコーポレイテッド Engineered target-specific base editors
WO2020047282A1 (en) 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
US11965154B2 (en) 2018-08-30 2024-04-23 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
WO2020061161A1 (en) 2018-09-18 2020-03-26 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for manufacturing lipid nanoparticles and liposomes
JP7460643B2 (en) * 2018-10-16 2024-04-02 ブルーアレル， エルエルシー Methods for targeted insertion of DNA into genes
JP7543259B2 (en) 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド Lipids for lipid nanoparticle delivery of active agents
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
AU2019368215B2 (en) 2018-10-22 2023-05-18 Inscripta, Inc. Engineered enzymes
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US20220023348A1 (en) 2018-11-28 2022-01-27 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
WO2020117862A1 (en) 2018-12-03 2020-06-11 Adicet Bio, Inc. Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof
KR20200071198A (en) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Development of new adoptive T cell immunotherapy by modification of Nrf2 expression
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
CA3120799A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
US20220090047A1 (en) 2018-12-21 2022-03-24 Precision Biosciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
MY202837A (en) 2019-01-11 2024-05-24 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active agents
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHODS OF TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE I
CN113631713A (en) 2019-03-25 2021-11-09 因思科瑞普特公司 Simultaneous multiplex genome editing in yeast
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
JP2022519949A (en) 2019-04-02 2022-03-25 サンガモ セラピューティクス， インコーポレイテッド Methods for the treatment of beta-thalassemia
JP7286796B2 (en) 2019-04-03 2023-06-05 プレシジョン バイオサイエンシズ，インク． Genetically modified immune cells containing microRNA-adapted SHRNA (SHRNAMIR)
WO2020206162A1 (en) 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
ES2966625T3 (en) 2019-04-04 2024-04-23 Regeneron Pharma Rodents comprising a humanized coagulation factor 12 locus
WO2020206134A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
AU2020254078B2 (en) 2019-04-05 2025-08-21 Osaka University Method for producing knock-in cell
EP3962519A1 (en) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
AU2020274996B2 (en) 2019-05-14 2024-02-01 Nuseed Nutritional Us Inc. Modified plants comprising a polynucleotide comprising a non-cognate promoter operably linked to a coding sequence that encodes a transcription factor
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US11845957B2 (en) 2019-06-14 2023-12-19 Regeneron Pharmaceuticals, Inc. Models of tauopathy
US10920189B2 (en) 2019-06-21 2021-02-16 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
WO2020254850A1 (en) 2019-06-21 2020-12-24 Vilmorin & Cie Improvement of quality and permanence of green color of peppers at maturity and over-maturity
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US20220267737A1 (en) 2019-07-18 2022-08-25 University Of Rochester Cell-type selective immunoprotection of cells
EP4004216A1 (en) 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
WO2021019272A1 (en) 2019-07-31 2021-02-04 Vilmorin & Cie Tolerance to tolcndv in cucumber
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
EP4057802A1 (en) 2019-11-14 2022-09-21 Vilmorin & Cie Resistance to acidovorax valerianellae in corn salad
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
EP4069285A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
KR102776469B1 (en) 2019-12-10 2025-03-05 인스크립타 인코포레이티드 Novel MAD nuclease
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
EP4069851A4 (en) 2019-12-18 2023-11-22 Inscripta, Inc. CASCADE/DCAS3 COMPLEMENTATION TESTS FOR IN VIVO DETECTION OF NUCLEIC ACID-DRIVEN NUCLEASE EDITED CELLS
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
AU2021213705A1 (en) 2020-01-27 2022-06-16 Inscripta, Inc. Electroporation modules and instrumentation
WO2021158915A1 (en) 2020-02-06 2021-08-12 Precision Biosciences, Inc. Recombinant adeno-associated virus compositions and methods for producing and using the same
CN115485385A (en) 2020-03-04 2022-12-16 瑞泽恩制药公司 Methods and compositions for sensitizing tumor cells to immunotherapy
WO2021195079A1 (en) 2020-03-23 2021-09-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
WO2021202513A1 (en) 2020-03-31 2021-10-07 Elo Life Systems Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
EP4146284A1 (en) 2020-05-06 2023-03-15 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
US20230212613A1 (en) 2020-05-06 2023-07-06 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
WO2021245435A1 (en) 2020-06-03 2021-12-09 Vilmorin & Cie Melon plants resistant to scab disease, aphids and powdery mildew
CA3186284A1 (en) 2020-06-05 2021-12-09 Vilmorin & Cie Resistance in plants of solanum lycopersicum to the tobrfv
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation IMPROVED VIRAL-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
CA3194019A1 (en) 2020-09-04 2022-03-10 National University Corporation Kobe University Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
WO2022060749A1 (en) 2020-09-15 2022-03-24 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
MA63547B1 (en) 2020-10-02 2025-08-29 Vilmorin & Cie EXTENDED SHELF LIFE MELON
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
US20240060079A1 (en) 2020-10-23 2024-02-22 Elo Life Systems Methods for producing vanilla plants with improved flavor and agronomic production
JP2023549780A (en) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド Cells expressing chimeric receptors from engineered invariant CD3 immunoglobulin superfamily chain loci and related polynucleotides and methods
EP4242237A4 (en) 2020-11-06 2025-01-01 Editforce, Inc. Foki nuclease domain variant
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
IL303102A (en) 2020-12-03 2023-07-01 Vilmorin & Cie Tomato plants resistant to tobrfv, tmv, tomv and tommv and corresponding resistance genes
AU2021415461A1 (en) 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
US20240376451A1 (en) 2021-01-07 2024-11-14 Inscripta, Inc. Mad nucleases
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
AR125199A1 (en) 2021-03-23 2023-06-21 Iovance Biotherapeutics Inc CISH GENE EDITION OF TUMOR-INFILTRATING LYMPHOCYTES AND THEIR USES IN IMMUNOTHERAPY
WO2022208489A1 (en) 2021-04-02 2022-10-06 Vilmorin & Cie Semi-determinate or determinate growth habit trait in cucurbita
WO2022226316A1 (en) 2021-04-22 2022-10-27 Precision Biosciences, Inc. Compositions and methods for generating male sterile plants
IL282597B (en) * 2021-04-22 2022-08-01 B G Negev Technologies And Applications Ltd At Ben Gurion Univ Birds for creating female offspring and methods for creating them
WO2022240846A1 (en) 2021-05-10 2022-11-17 Sqz Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
KR20240027676A (en) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. NR4A3-deficient immune cells and uses thereof
US20250280784A1 (en) 2021-08-06 2025-09-11 Vilmorin & Cie Resistance to leveillula taurica in pepper
WO2023035011A1 (en) 2021-09-03 2023-03-09 North Carolina State University Compositions and methods for conferring resistance to geminivirus
JP7125727B1 (en) 2021-09-07 2022-08-25 国立大学法人千葉大学 Compositions for modifying nucleic acid sequences and methods for modifying target sites in nucleic acid sequences
WO2023039598A1 (en) 2021-09-13 2023-03-16 Life Technologies Corporation Gene editing tools
US20240336896A1 (en) 2021-10-14 2024-10-10 Lonza Sales Ag Modified producer cells for extracellular vesicle production
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
EP4419111A1 (en) 2021-10-19 2024-08-28 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
WO2023076897A1 (en) 2021-10-25 2023-05-04 Fios Therapeutics, Llc Viable galactosyltransferase knock-out sheep and related methods
US12275947B2 (en) 2021-10-25 2025-04-15 Fios Therapeutics, Llc Viable genetically modified sheep with an inactivated alpha-1,3-galactosyltransferase (GGTA1) gene
US20230149563A1 (en) 2021-10-27 2023-05-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for expressing factor ix for hemophilia b therapy
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
CN118632622A (en) 2021-12-08 2024-09-10 瑞泽恩制药公司 Mutant myocilin disease model and its use
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
KR20240128067A (en) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 Generation of landing pad cell lines
EP4460571A1 (en) 2022-01-05 2024-11-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
EP4473103A2 (en) 2022-02-02 2024-12-11 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
US20250194571A1 (en) 2022-02-07 2025-06-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
US20230257432A1 (en) 2022-02-11 2023-08-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
US20250186614A1 (en) 2022-03-18 2025-06-12 Obsidian Therapeutics, Inc. Compact drug responsive domains for regulation of function/abundance and delivery of polypeptide payloads
EP4256950A1 (en) 2022-04-06 2023-10-11 Vilmorin et Cie Tolerance to cgmmv in cucumber
US20250302998A1 (en) 2022-05-09 2025-10-02 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
KR20250027283A (en) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. Polynucleotide targeting nr4a3 and uses thereof
GB2621813A (en) 2022-06-30 2024-02-28 Univ Newcastle Preventing disease recurrence in Mitochondrial replacement therapy
IL318625A (en) 2022-07-29 2025-03-01 Regeneron Pharma Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
IL318553A (en) 2022-08-05 2025-03-01 Regeneron Pharma Aggregation-resistant variants of tdp-43
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN120265314A (en) 2022-09-28 2025-07-04 瑞泽恩制药公司 Antibody-resistant modified receptors to enhance cell-based therapies
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
IL320016A (en) 2022-11-04 2025-06-01 Regeneron Pharma Voltage-gated calcium channel auxiliary subunit gamma 1 (CACNG1) binding proteins and CACNG1-assisted skeletal muscle delivery
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
IL321652A (en) 2022-12-29 2025-08-01 Vilmorin & Cie Tomato plants resistant to resistance-breaking tswv strains and corresponding resistance genes
CN121002052A (en) 2023-02-03 2025-11-21 C3S2 有限公司 Methods for engineered immune cells used in non-viral production
US12239091B2 (en) 2023-03-27 2025-03-04 Redsea Science And Technology Inc. Tomato plant designated ‘MX20-06’
WO2024216116A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
KR20260010765A (en) 2023-04-14 2026-01-21 프리시젼 바이오사이언시스 인코포레이티드 Muscle-specific expression cassette
EP4701406A1 (en) 2023-04-28 2026-03-04 Vilmorin & Cie Genetic determinants conferring improved tobrfv resistance
WO2025003305A1 (en) 2023-06-28 2025-01-02 Vilmorin & Cie Pepper resistance to meloidogyne enterolobii
WO2025021893A1 (en) 2023-07-24 2025-01-30 Vilmorin & Cie Resistance to cysdv in melons
AU2024315073A1 (en) 2023-07-28 2026-01-22 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
AU2024317483A1 (en) 2023-07-28 2026-01-29 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
WO2025049524A1 (en) 2023-08-28 2025-03-06 Regeneron Pharmaceuticals, Inc. Cxcr4 antibody-resistant modified receptors
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
GB202314578D0 (en) 2023-09-22 2023-11-08 Univ Manchester Methods of producing homoplasmic modified plants or parts thereof
WO2025147573A2 (en) 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025186284A1 (en) 2024-03-05 2025-09-12 Vilmorin & Cie Increased yield in cucumber
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025235388A1 (en) 2024-05-06 2025-11-13 Regeneron Pharmaceuticals, Inc. Transgene genomic identification by nuclease-mediated long read sequencing
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2025259554A1 (en) 2024-06-13 2025-12-18 J.R. Simplot Company Engineering remontant flowering in rosaceae
WO2025265017A1 (en) 2024-06-20 2025-12-26 Regeneron Pharmaceuticals, Inc. Ass1 gene insertion for the treatment of citrullinemia type i
WO2026017833A1 (en) 2024-07-17 2026-01-22 Vilmorin & Cie Tswv-resistant pepper
WO2026072529A1 (en) 2024-09-24 2026-04-02 University Of Florida Research Foundation, Incorporated Mettl7a for improved embryo competence

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942227A (en) * 1982-01-11 1990-07-17 California Institute Of Technology Bifunctional molecules having a DNA intercalator or DNA groove binder linked to ethylene diamine tetraacetic acid, their preparation and use to cleave DNA
US4665184A (en) * 1983-10-12 1987-05-12 California Institute Of Technology Bifunctional molecules having a DNA intercalator or DNA groove binder linked to ethylene diamine tetraacetic acid
US4795700A (en) * 1985-01-25 1989-01-03 California Institute Of Technology Nucleic acid probes and methods of using same
US5789155A (en) * 1987-10-30 1998-08-04 California Institute Of Technology Process for identifying nucleic acids and triple helices formed thereby
US5955341A (en) * 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792640A (en) * 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5916794A (en) * 1992-04-03 1999-06-29 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5487994A (en) * 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) * 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5496720A (en) * 1993-02-10 1996-03-05 Susko-Parrish; Joan L. Parthenogenic oocyte activation
US6331658B1 (en) * 1993-04-20 2001-12-18 Integris Baptist Medical Center, Inc. Genetically engineered mammals for use as organ donors
US6242568B1 (en) * 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) * 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
ATE524545T1 (en) * 1994-08-20 2011-09-15 Gendaq Ltd IMPROVEMENTS IN OR RELATED TO BINDING PROTEINS FOR DNA DETECTION
US6326166B1 (en) * 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
AU6096296A (en) 1995-06-07 1996-12-30 Ohio State University, The Artificial restriction endonuclease
GB9517780D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US6265196B1 (en) * 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5928914A (en) 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
US5945577A (en) * 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6781035B1 (en) * 1997-02-21 2004-08-24 The Regents Of The University Of California Leafy cotyledon1 genes and their uses
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
AU757930B2 (en) 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
DE69942334D1 (en) * 1998-03-02 2010-06-17 Massachusetts Inst Technology POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS
AU772879B2 (en) 1998-08-12 2004-05-13 Napro Biotherapeutics, Inc. Domain specific gene evolution
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US20020151017A1 (en) 1998-11-10 2002-10-17 Willem P. C. Stemmer Methods for obtaining a polynecleotide encoding a polypeptide having a rubisco activity
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
WO2000046386A2 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
JP2002535994A (en) * 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション Gene repair by in vivo removal of target DNA
US6977295B2 (en) 1999-04-21 2005-12-20 Invitrogen Corporation Locked nucleic acid hybrids and methods of use
EP1194540A1 (en) 1999-07-14 2002-04-10 Clontech Laboratories Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
CA2394850C (en) 1999-12-06 2012-02-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7151201B2 (en) * 2000-01-21 2006-12-19 The Scripps Research Institute Methods and compositions to modulate expression in plants
WO2001059094A2 (en) * 2000-02-11 2001-08-16 The Salk Institute For Biological Studies Method of regulating transcription in a cell by altering remodeling of cromatin
WO2001066717A2 (en) 2000-03-03 2001-09-13 The University Of Utah Gene targeting method
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US7091026B2 (en) * 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
SI2049663T1 (en) 2006-08-11 2015-12-31 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
DK2205749T3 (en) 2007-09-27 2016-08-22 Dow Agrosciences Llc MODIFIED PROTEINS zinc finger, which target the 5-enolpyruvylshikimate-3-phosphate synthase genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIBIKOVA ET AL.: "Enhancing gene targeting with designed zinc finger nucleases", SCIENCE, vol. 300, 2 May 2003 (2003-05-02), pages 764, XP002974267 *
BIBIKOVA ET AL.: "Stimulation of homologous recombination through targeted cleavage by chimeric nucleases", MOLECULAR AND CELLULAR BIOLOGY, vol. 21, no. 1, January 2001 (2001-01-01), pages 289 - 297, XP002974229 *
BIBIKOVA ET AL.: "Targeted chromosomal cleavage and mutagenesis in drosophila using zinc-finger nucleases", GENETICS, vol. 161, July 2002 (2002-07-01), pages 1169 - 1175, XP002261110 *
CHANDRASEGARAN ET AL.: "Chimeric restriction enzymes: what is next?", BIOLOGICAL CHEMISTRY, vol. 380, July 1999 (1999-07-01) - August 1999 (1999-08-01), pages 841 - 848, XP008019125 *
PORTEUS AND BALTIMORE: "GFP Gene Targeting System", pages 1 - 12, XP002974232, Retrieved from the Internet <URL:www.sciencemag.org/cgi/content/full/300/5620/763/DC1> *
PORTEUS ET AL.: "Chimeric nucleases stimulate gene targeting in human cells", SCIENCE, vol. 300, 2 May 2003 (2003-05-02), pages 763, XP002974231 *
SEGAL D.J.: "The use of zinc finger peptides to study the role of specific factor binding sites in the chromatin environment", METHODS, vol. 26, 2002, pages 76 - 83, XP002974227 *
SMITH ET AL.: "Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains", NUCLEIC ACIDS RESEARCH, vol. 28, no. 17, 2000, pages 3361 - 3369, XP002974228 *
WILSON J.H.: "pointing fingers at te limiting step in gene targeting", NATURE BIOTECHNOLOGY, vol. 21, no. 7, July 2003 (2003-07-01), pages 759 - 760, XP002974230 *
XP002974268, Retrieved from the Internet <URL:www.sciencemag.org/cgi/content/full/300/5620/763/DC1> *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591592B2 (en) 2020-04-24 2023-02-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells using microcarriers
US11845932B2 (en) 2020-04-24 2023-12-19 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery

Also Published As

Publication number Publication date
CN1622993A (en) 2005-06-01
EP1476547A2 (en) 2004-11-17
AU2003251286A1 (en) 2003-10-27
DE60310202T2 (en) 2007-11-22
JP2009195256A (en) 2009-09-03
US20110014601A2 (en) 2011-01-20
JP2005519631A (en) 2005-07-07
US20200231979A1 (en) 2020-07-23
EP1476547B1 (en) 2006-12-06
AU2003251286B2 (en) 2007-08-16
BRPI0307383B1 (en) 2019-12-31
US20120219959A1 (en) 2012-08-30
US20050208489A1 (en) 2005-09-22
ATE347593T1 (en) 2006-12-15
US20160076045A1 (en) 2016-03-17
US8106255B2 (en) 2012-01-31
CA2474486C (en) 2013-05-14
CN100575485C (en) 2009-12-30
WO2003087341A2 (en) 2003-10-23
BR0307383A (en) 2005-04-26
CA2474486A1 (en) 2003-10-23
JP4968498B2 (en) 2012-07-04
EP1476547A4 (en) 2005-08-17
DE60310202D1 (en) 2007-01-18
US9145565B2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
WO2003087341A3 (en) Targeted chromosomal mutagenesis using zinc finger nucleases
WO2004037977A3 (en) Use of chimeric nucleases to stimulate gene targeting
WO2003080807A3 (en) Compositions and methods for suppressing eukaryotic gene expression
WO2003064625A3 (en) Oligonucleotide compositions with enhanced efficiency
WO2005049842A3 (en) Improved targeted dna insertion in plants
WO2003062394A3 (en) Methods and compositions for rna interference
AU2004802A (en) Methods of modifying eukaryotic cells
MX343591B (en) Methods of modifying eukaryotic cells.
WO2006078414A3 (en) METHODS AND COMPOSITIONS CONCERNING siRNA&#39;S AS MEDIATORS OF RNA INTERFERENCE
WO2002026967A3 (en) Targeted gene correction by single-stranded oligodeoxynucleotides
EP2368982A3 (en) Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
WO2002000904A3 (en) Recombinant constructs and their use in reducing gene expression
MX2007004610A (en) Enzymes.
WO2004022738A8 (en) Methods and compositions for the generation of humanized mice
MXPA06000092A (en) Chloroplast transformation of duckweed.
EP2275546A3 (en) Enzymatic DNA molecules
WO2001066717A8 (en) Gene targeting method
SI1675954T1 (en) Nucleic acids useful for triggering tumor cell lethality
WO2003027261A3 (en) Methods and compositions for gene targeting by homologous recombination
WO2002008432A3 (en) Composition and method for increased meiotic recombination in plants
WO2002010364A3 (en) Methods for enhancing targeted gene alteration using oligonucleotides
MXPA02012557A (en) Nucleic acid sequences and methods for the modification of plant gene expression.
WO2002006495A3 (en) Mutant muscle-specific enhancers
WO2004070035A3 (en) Method for increasing efficiency of homologous recombination in plants
WO2003069311A3 (en) Methods and compositions for use in spliceosome mediated rna trans-splicing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003251286

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10502565

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2474486

Country of ref document: CA

Ref document number: 20038026643

Country of ref document: CN

Ref document number: 2003584285

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003746527

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003746527

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003746527

Country of ref document: EP